- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01894646
PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA
Currently, only three radiotracers, (2-[18F]FA, 6-[18F]FA and [18F]AZAN), are available for studying α4β2-nicotinic acetylcholine receptors (α4β2-nAChR) in human brain using PET imaging. A crucial problem for 2-[18F] FA, 6-[18F] FA and ([18F] AZAN is low binding potential (BP) in extrathalamic (ET) regions, including hippocampus, cortex and caudate which have lower receptor densities than the thalamus. The importance of imaging ET-α4β2-nAChRs (ET-nAChR) has emerged from the post-mortem demonstration of altered densities of ET-nAChRs (but not thalamic nAChR) in neurodegenerative diseases and schizophrenia. PET imaging of ET-nAChR may prove to be useful in both detecting early changes and following functional deterioration in neurodegenerative diseases such as Alzheimers disease. Furthermore, PET imaging of ET-nAChR may allow investigation and development of new therapies acting on the acetylcholine system.
The imaging drawbacks of the presently available nAChR radioligands have initiated the development of radioligands with greater binding potential by several research groups. The available pre-clinical data on the investigators' new radioligand [18F](-)-JHU86428 ([18F]XTRA) suggest that this radioligand is superior to 2-[18F]FA for quantitative PET imaging of α4β2-nAChR (Gao, J. Med. Chem, 2008). In baboon PET studies [18F]XTRA exhibits 200% greater brain uptake, 300% higher BPs and reaches steady-state in approximately 1.5 h in cortical regions post-bolus administration versus 6-8 h for 2-[18F]FA. In vitro binding assays shows greater binding affinity of XTRA and similar nAChR-subtype selectivity in comparison with 2-FA. Both ligands bind selectively with the β2-subtypes that are predominant nAChR subtypes in the mammal brain and display little binding affinity at ganglionic α3β4-nAChR.
The current planned human protocol will be conducted to (1) determine brain distribution (brain uptake) and test the reproducibility (in test-retest design) of [18F]XTRA brain PET scans for validation of the radioligand; (2) generate estimates of the whole body and internal organ radiation absorbed doses from exposure to single iv administrations of [18F]XTRA in healthy human subjects; and (3) determine brain distribution of [18F]XTRA in patients with Alzheimer's disease.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The population consists of healthy adults 18-85 years of age. There is no race or sex bias in our recruitment.
a. Inclusion criteria.
- healthy volunteer, 18-80 years of age, and in portion 2, patient with Alzheimer's disease or patient with mild cognitive impairment (age 60-80 years)
- screening laboratory tests will be obtained for subjects within a 10-day period prior to the PET study and the results must be within normal limits for gender and age. These tests will be repeated with a 10-day window following the PET study.
- ECG conducted within a 10-day period prior to the PET study. The ECG will be repeated within 10 days following the study.
- No contraindications to MRI scanning if MRI is to be obtained in the section for which the subject participates. These contraindications include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc.
- No contraindications to PET scanning to include pregnancy, etc. For females of childbearing potential, negative serum pregnancy test obtained within a 10-day period prior to PET study
- Subject agrees to return to the Hospital for f/u ECG and laboratory testing of blood and urine
Exclusion Criteria:
- Participants with history of epilepsy, focal structural CNS abnormality such as stroke, or arteriovenous malformation
- History of head injury with loss of consciousness > 1 hour,
- Active substance abuse (drugs or alcohol) or active nicotine use
- ECG demonstrating the participant is not in a sinus rhythm or is having acute ischemia
- Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
- Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Young healthy individuals (ages 18-50)
Positron Emission Tomography (PET) Imaging
|
|
Experimental: Elderly healthy individuals (ages 60-85)
Positron Emission Tomography (PET) Imaging
|
|
Other: Patients with Alzheimer's disease or mild cognitive impairment
Positron Emission Tomography (PET) Imaging
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PET Imaging of extrathalamic α4β2-nicotinic acetylcholine receptors in health and disease with [18F]XTRA
Time Frame: 1 year
|
Measures brain uptake of F18 XTRA
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NA_00076249
- 1R21AG037298-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Measure of Uptake of XTRA in the Brain
-
University Hospital, BrestCompletedMeasure of the X-ray DoseFrance
-
Church & Dwight Company, Inc.Medical University of South CarolinaCompletedMeasure Absorption of Vitamin D in BloodUnited States
-
University Hospital, GasthuisbergCompletedthe Focus of This Study is to Measure the Intra- and Interobserver Agreement for the Evaluation of Early Stage EmbryosBelgium
-
Assiut UniversityNot yet recruitingPossibility of Using microRNA30a as a Prognostic Marker in Philadelphia Positive Leukemic Patients by Measure Level of microRNA30a in Blood Sample
-
Baylor College of MedicineRecruitingThe Aim of This Study is to Measure Blood Flow Before and After a BlockUnited States
-
Copenhagen Trial Unit, Center for Clinical Intervention...The Info Trial Group; Charlotte Behnke; Pia Caspersen; Dorte Fischer; Rolf I. Hansen and other collaboratorsCompletedAmbulatory Patients in the Dep. of Medical Gastroenterology | Ambulatory Patients in the Dep. of Gynecology | Ambulatory Patients in the Dep. of Orthopedic Surgery | Ambulatory Patients in the Dep. of UrologyDenmark
-
The University of Tennessee, KnoxvilleCompletedMeasure Grams and Kcals of Snack Foods Consumed in Each ConditionUnited States
-
OSF Healthcare SystemUniversity of Illinois College of Medicine at PeoriaCompletedthe Focus of the Clinical Trial is on the Brain Temperatures in Normal Human SubjectsUnited States
-
Medical University of SilesiaCompletedChanges in Blood Flow to the Brain | Changes Depending on the Form of WalkingPoland
-
Klinikum der Universität KölnUnknownChanges in Six Minute Walking Distance, Peak Oxygen Uptake, Quality of LifeGermany
Clinical Trials on Positron Emission Tomography (PET) Imaging
-
Jagiellonian UniversityMedical University of WarsawCompletedNeurodegenerative Diseases | Brain Neoplasms | Neuroendocrine TumorsPoland
-
NYU Langone HealthYale UniversityTerminatedPost-traumatic Stress Disorder (PTSD)United States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnOropharyngeal Squamous Cell Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma
-
Chinese PLA General HospitalUnknown
-
Stanford UniversityNational Cancer Institute (NCI)CompletedPancreatic Carcinoma | Healthy SubjectUnited States
-
Stanford UniversityRecruiting
-
University of Texas Southwestern Medical CenterWithdrawn
-
The Hospital for Sick ChildrenCompleted